Drug Profile
Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics
Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB-282; ATB-284; ATB-427; ATB-428; ATB-429Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Antibe Therapeutics
- Class Analgesics; Anti-inflammatories; Anticoagulants; Irritable bowel syndrome therapies; Small molecules; Sulfides; Vasodilators
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Irritable bowel syndrome
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Canada
- 29 Jun 2023 Antibe Therapeutics files for patent protection for hydrogen sulfide-based therapeutic candidate(s) for inflammatory bowel disease (IBD)
- 15 Aug 2022 Antibe Therapeutics anticipates identification of lead candidates in Inflammatory bowel diseases in Q4 2022